DNL-151
- Generic Name
- DNL-151
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 18
- Registration Number
- NCT06264440
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
- Conditions
- Parkinson Disease
- Interventions
- Drug: BIIB122-Matching Placebo
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 7
- Registration Number
- NCT05418673
- Locations
- 🇺🇸
Rocky Mountain Movement Disorders Center, PC, Englewood, Colorado, United States
🇺🇸Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
🇺🇸Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
- Conditions
- Parkinson Disease
- Interventions
- Drug: BIIB122-Matching Placebo
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 650
- Registration Number
- NCT05348785
- Locations
- 🇫🇷
Hopital Henri Mondor, Paris, France
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Banner Sun Health Research Institute, Sun City, Arizona, United States
A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 84
- Registration Number
- NCT05229562
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT04557800
- Locations
- 🇳🇱
PRA Health Sciences, Van Swietenlaan, Groningen, Netherlands
🇳🇱Centre for Human Drug Research, Leiden, South Holland, Netherlands
Study to Evaluate DNL151 in Subjects With Parkinson's Disease
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT04056689
- Locations
- 🇳🇱
QPS, Leeuwarden, Netherlands
🇬🇧Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, United Kingdom
🇧🇪UZ Leuven, Leuven, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.